Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07313215) titled 'Rifampin-combined Antibiotic Therapy for Staphylococcal PJI' on Dec. 17, 2025.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: First Affiliated Hospital of Fujian Medical University

Condition: Periprosthetic Joint Infection

Intervention: Drug: Rifampicin (R)

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: November 13, 2025

Target Sample Size: 428

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07313215

Published ...